Xenetic Biosciences Expands Management Team with Key Appointment of Jeffrey F. Eisenberg as Chief Operating Officer Dec 5, 2016
Xenetic Biosciences Appoints Edward J. Benz, Jr., M.D., Former Dana-Farber CEO, to its Board of Directors Nov 22, 2016
Xenetic Biosciences Reports Third Quarter Financial Results and Provides Business Update Nov 15, 2016
Xenetic Biosciences Announces Nasdaq Listing of its Common Stock and Pricing of $10M Public Offering Nov 1, 2016
Xenetic Biosciences Reports Positive Topline Data from Third Cohort of Phase 2 Dose-Escalation Trial of ErepoXen® for Anemia Oct 10, 2016
Xenetic Biosciences Announces FDA Acceptance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of Virexxa® in Endometrial Cancer Aug 19, 2016
